Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 82656 refers to a laboratory test that assesses the presence of pancreatic elastase (EL-1) in fecal samples, providing either a qualitative or semi-quantitative result. Pancreatic elastase is a glycoprotein digestive enzyme produced by the acinar cells of the pancreas. Once synthesized, it is released into the intestine, where it plays a crucial role in the digestion of food, aiding in the absorption of nutrients. Additionally, pancreatic elastase interacts with bile acids and neutral steroids to facilitate the transport of cholesterol within the body. The fecal test for EL-1 is particularly valuable in monitoring pancreatic function, especially in patients diagnosed with cystic fibrosis. Furthermore, this test can assist healthcare providers in diagnosing or ruling out conditions associated with pancreatic exocrine insufficiency, which may arise from chronic pancreatitis, cystic fibrosis, pancreatic tumors, cholelithiasis, or diabetes mellitus. It is important to note that prior to conducting this test, any pancreatic enzyme supplements should be discontinued to ensure accurate results. The test involves collecting a sample of formed stool in a clean container, which is then analyzed using the enzyme-linked immunosorbent assay (ELISA) method. For quantitative measurements of pancreatic elastase, the CPT® Code 82653 should be reported, while CPT® Code 82656 is designated for qualitative or semi-quantitative assessments of EL-1 presence.
© Copyright 2026 Coding Ahead. All rights reserved.
The fecal test for pancreatic elastase (EL-1) is indicated for several clinical scenarios, particularly in assessing pancreatic function and diagnosing related conditions. The following are the specific indications for performing this test:
The procedure for conducting the fecal test for pancreatic elastase (EL-1) involves several key steps to ensure accurate results. The following outlines the procedural steps:
After the fecal test for pancreatic elastase (EL-1) is completed, there are no specific post-procedure care requirements mentioned. However, it is advisable for patients to consult with their healthcare provider regarding the interpretation of test results and any necessary follow-up actions. The results can provide valuable insights into pancreatic function and guide further diagnostic or therapeutic decisions based on the findings.
| Short Descr | EL-1 FECAL QUAL/SEMIQ | Medium Descr | ELASTASE PANCREATIC FECAL QUAL/SEMI-QUANTITATIVE | Long Descr | Elastase, pancreatic (EL-1), fecal; qualitative or semi-quantitative | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 235 - Other Laboratory |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GZ | Item or service expected to be denied as not reasonable and necessary | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Changed | Small & Medium descriptions changed. |
| 2022-01-01 | Note | Long description grammar change |
| 2011-01-01 | Changed | Short description changed. |
| 2005-01-01 | Added | First appearance in code book in 2005. |
| 1992-12-31 | Deleted | Code deleted. |
Get instant expert-level medical coding assistance.